Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
The stock price of MiMedx plummeted 35% Tuesday morning after the company, which sells products for burns and wound care, said it was postponing the release of its 2017 financial results due to an internal investigation of its sales practices.
Why it matters: Short sellers like Marc Cohodes have long alleged MiMedx fraudulently inflated its sales numbers. Delaying the financials, at a minimum, is a public-relations disaster and could indicate deeper trouble from government auditors.
Go deeper: MiMedx CEO Pete Petit is a big backer of President Trump and former health secretary Tom Price, and Petit's feud with short sellers reached a boiling point this past January.